healios labs Expertise
Dosage Forms Expertise
At Healios Labs, dosage-form development is engineered as an end-to-end scientific pathway—beginning with preformulation intelligence, moving through process-design optimization, and culminating in commercial-scale manufacturability. Every program is de-risked through data-driven formulation strategies, advanced material-science characterization, and device–product compatibility mapping. Whether the challenge is solubility enhancement, aseptic precision, modified-release engineering, or complex delivery routes, Healios integrates deep technical fluency with industrial execution to deliver robust, regulatory-aligned products with predictable performance and seamless scale-up trajectories.
Transdermals
Design and optimization of matrix patches, reservoir systems, adhesive laminates, and drug-in-adhesive technologies. Capabilities include in-vitro permeation testing (IVPT), skin flux optimization, adhesive–drug compatibility, and long-duration controlled release to meet systemic delivery targets.
Ophthalmics
Development of sterile solutions, suspensions, emulsions, and in-situ gelling systems, supported by low-endotoxin raw material selection, particle-size control, viscosity modulation, and preservative-free multi-dose systems. Expertise extends to osmolarity balancing, ocular tolerability studies, and device-matching for droppers and precision-dose systems.
Injectables (SVP & LVP)
Capabilities cover aqueous and non-aqueous solutions, suspensions, emulsions, lyophilized powders, ready-to-use and ready-to-dilute formats. Specialization includes complex injectables using vials, ampoules, prefilled syringes, auto-injectors, and pen systems. Technical depth spans sterile filtration feasibility, container–closure integrity (CCI), cryo- and thermo-stabilization, solubility enhancers, and depot technologies.
Nasal Sprays (Unidose, Bidose, Multidose)
Advanced formulation of aqueous, non-aqueous, powder, and mucoadhesive nasal systems, including particle-size optimization for olfactory or respiratory targeting, spray pattern characterization, plume geometry, pump/actuator compatibility, and device performance verification.
Inserts (Suppositories, Pessaries, Bougies)
Development of lipidic, polymeric, and thermo-responsive insert technologies, with control over melt characteristics, dissolution/erosion dynamics, mucosal retention, and local or systemic delivery performance.
Otic
Design of viscous solutions, suspensions, and oil-based systems optimized for residence time, middle-ear penetration, antimicrobial preservative systems, and stability of moisture-sensitive APIs.
Implants (Subdermal, Ocular, Vaginal, Rectal)
Expertise in PLGA-based depot implants, osmotic implants, polymeric rods, and device-integrated implant systems. Capabilities include drug-polymer compatibility mapping, release-kinetics modeling, in-vitro/in-vivo correlation (IVIVC), sterilization validation, and scalable manufacturing pathways.
Oral Liquids
Formulation of solutions, suspensions, syrups, and pediatric-friendly formats using solubilizers, pH modifiers, taste-masking agents, and viscosity enhancers. Expertise in physical stability, rheology tuning, and microbial preservation, particularly for low-solubility molecules.
Drug Modalities
Healios Labs operates at the intersection of complex chemistry, biotransformation science, and advanced containment technologies to support an exceptionally broad spectrum of drug modalities. From highly potent APIs to structurally delicate peptides and carbohydrate-based scaffolds, our teams architect formulation and process solutions that stabilize challenging molecules, mitigate degradation pathways, and ensure dose-precision across delivery routes. By integrating high-resolution analytical control with modality-specific manufacturing infrastructure, Healios delivers development programs that are scientifically rigorous, cGMP-compliant, and ready for seamless transition into clinical or commercial supply.
Controlled Substances (Schedule II–V)
Secure development infrastructure with chain-of-custody controls, DEA-compliant warehousing, validated access protocols, and experience with abuse-deterrent excipients and manipulation-resistant formulations.
Hormonal Products
Handling of estrogens, progestins, androgens, and peptide hormones, with careful control of potency, light/oxidative degradation pathways, and matrix/vehicle optimization for stable release.
Steroidal Products
Development of topical, injectable, and ophthalmic steroidal formulations with emphasis on crystallinity control, particle engineering, and suspension stability.
Cytotoxic Drugs
Isolated, negative-pressure suites for high-potency handling, with closed-system compounding, robust decontamination protocols, and specialized containment for multi-step processing.
Synthetic Peptides
Expertise includes solubility enhancement, aggregation prevention, oxidative stability, and formulation strategies such as lyophilization, liposomal encapsulation, and soft-mist intranasal delivery.
Complex Carbohydrates
Capabilities include hygroscopic excipient handling, stability enhancement via pH/osmolar control, and structure-preservation strategies for sensitive polysaccharide-based APIs.
Complex Small Molecules
Specialized approaches for molecules with pKa challenges, polymorphism risks, low solubility, permeability barriers, or metabolic instability, supported by advanced screening and modeling tools.
Drug–Device Combinations
Drug–device combinations demand a sophisticated fusion of formulation science, human-factors engineering, micro-mechanical design, and performance-critical material selection. Each system must harmonize dose uniformity, device actuation mechanics, extractables/leachables control, container–closure integrity, and user-interface safety—all under stringent regulatory scrutiny. Healios Labs builds these hybrids with an integrated platform that aligns API behavior with device architecture, validates functional reliability through accelerated stress-mapping, and engineers delivery systems optimized for accuracy, usability, and lifecycle robustness. Our multidisciplinary ecosystem ensures seamless convergence of drug, device, and manufacturing design to achieve consistent, clinic-ready performance.
Prefilled & Ready-to-Go Systems
End-to-end development including PFS compatibility, extractables/leachables, silicone-oil control, needle gauge optimization, and glide-force tuning.
Transdermal & Dermal Systems
Device-integrated patches, microneedles, iontophoretic systems, and multi-layer laminate configurations with validated flux, wear-time, and adhesion performance.
Implantable Drug–Device Hybrids
Combination implants integrating polymeric matrices, reservoirs, metallic components, and programmable release systems with complete biocompatibility and sterilization validation.
Nasal Delivery with Devices
Integration of unit-dose/bidose systems, multidose pumps, breath-powered devices, and performance testing using spray geometry, plume consistency, DDU, and APSD.
Inhalation-Based Devices
Capability to support DPIs, MDIs, nebulizers, with expertise in aerodynamic particle-size (MMAD), fine-particle fraction (FPF), propellant compatibility, and container-device-formulation integration.
Ophthalmic Drug–Device Products
Includes preservative-free multi-dose systems, specialty droppers, metered-dose ocular sprays, and advanced devices for precise dose delivery.
Novel Drug Delivery Systems Across Multiple Routes
Novel drug delivery systems require a sophisticated command of biopharmaceutics, tissue-specific transport mechanisms, excipient functionality, and device–interface optimization. Achieving targeted deposition—whether across dermal layers, ocular surfaces, pulmonary architecture, or mucosal pathways—demands precision engineering backed by mechanistic ADME insights. Healios Labs integrates advanced permeability modeling, rheological tuning, micro/nano-scale carrier design, and route-specific release engineering to build delivery systems that unlock therapeutic access where conventional formats fail. Our cross-route development framework ensures each platform is scientifically validated, manufacturable, and engineered for predictable in-vivo performance.
Rectal & Vaginal Delivery
Complex semisolid and insert systems with mucosal adhesion, controlled erosion kinetics, and high-retention performance for local and systemic targets.
Otic Delivery
Enhanced-residence formulations with thermoreversible gels, viscosity modulation, and penetration enhancers for deeper tissue engagement.
Ungual & Transungual Delivery
Specialized formulations for onychoprotection, keratin permeation enhancement, and long-term localized release for nail disorders.
Para-IV Formulation Development
Para-IV development requires a strategic blend of formulation invention, regulatory dexterity, and deep mechanistic understanding of reference-listed drugs. The challenge lies in engineering a therapeutically equivalent yet non-infringing product by modulating composition, microstructure, release kinetics, or manufacturing pathways—without compromising QTPP alignment. Healios Labs brings patent-deconstruction expertise, excipient-function redesign, physicochemical pathway mapping, and complex-generic development capability to architect formulations that withstand legal scrutiny, achieve bioequivalence, and deliver first-to-file competitive advantage with technical defensibility.
Q1/Q2-Different Formulations
Strategic formulation variance to enable non-equivalent but bioequivalent products using functional excipient substitution, particle engineering, or controlled microstructure variance.
Alternative Dosage Form
Switching formats (e.g., gel → cream, solution → suspension) to navigate around patents while maintaining therapeutic equivalence.
Alternative Strength or Release Profile
Leveraging MR/ER/DR modifications, strength optimization, or dose-proportionality engineering to create differentiated yet bioequivalent profiles.
Polymorph / Salt / Co-crystal Switching
IP-smart switching of crystalline forms, counter-ions, or co-formers to yield improved solubility, stability, or manufacturability.
Excipient-Function Shift
Rearchitecting formulation roles (binder → matrix former, surfactant → release modulator) to unlock mechanistic workarounds.
Manufacturing-Process Differentiation
Strategic changes in granulation, particle-size distribution, sterilization methods, lyophilization design, or processing sequence to bypass IP.
Abuse-Deterrent Strategy Modification
Designing formulations using viscosity enhancers, melt-resistant matrices, antagonist incorporation, or physical/chemical manipulation barriers.
Device or Delivery-Component Modification
Substituting delivery interfaces (PFS → vial, actuator variants, spray mechanics) to differentiate the product.
Complex Generics Para-IV
Development for peptides, liposomes, nano-systems, and depot formulations using advanced characterization, in-vitro release modeling, and bioequivalence pathways.
505(b)(2) Formulation Development
Navigating the 505(b)(2) regulatory pathway demands an intricate balance of scientific innovation, clinical justification, and regulatory strategy. Healios Labs excels in translating novel formulation concepts into viable products while ensuring alignment with FDA expectations. Our capabilities address key challenges including route modification, strength optimization, release profile engineering, and patient-centric design, while maintaining robust analytical characterization and device integration. From combination products to prodrug innovations, Healios delivers technically sound, scalable, and regulatory-ready 505(b)(2) solutions, minimizing development risks and accelerating time-to-market.
New Dosage Form
Transforming existing drugs into patches, sprays, films, implants, or long-acting injectables with supportive PK and clinical data.
New Route of Administration
Re-engineering systemic drugs for ocular, nasal, pulmonary, transdermal, or implantable routes to improve safety or compliance.
New Strength / Dosing Regimen
Precision optimization for pediatric, geriatric, or chronic use, enabled by PK modeling and modified-release technologies.
Modified Release Formulations
Hydrophilic matrices, osmotic systems, lipid-based ER systems, and biphasic release architecture.
Novel Excipient or Excipient Function
Incorporation of amorphous stabilizers, solubilizing lipids, penetration enhancers, or functional polymers for new performance benefits.
Combination Products
Drug–drug or drug–device combinations designed for synergistic efficacy, improved adherence, or unique delivery.
Reformulated Complex Products
Reworking sterile, ophthalmic, or inhalation products with improved stability, usability, or device compatibility.
New Indication or Population
Formulations adjusted for PK tailoring, tolerability improvements, and patient-centric attributes.
Prodrugs and Salt/Cocrystal Variants
Scientific redesign for improved solubility, PK, or stability with full characterization and regulatory support.
Reformulation for Safety/Tolerability
Minimizing irritancy, peak-trough fluctuations, excipient toxicity, or dose-related side effects.
NCE Formulation Development
Developing formulations for New Chemical Entities (NCEs) presents unique scientific challenges, from solubility and stability constraints to bioavailability optimization and early-stage enablement. Healios Labs leverages cutting-edge formulation science to address these hurdles, including advanced delivery platforms, prodrug strategies, and bioenhancement techniques. Our expertise spans preclinical to Phase I enablement, allowing seamless scale-up and integration with clinical supply chains. By combining mechanistic understanding with process engineering, Healios ensures robust, reproducible, and regulatory-compliant NCE formulations that maximize therapeutic potential while mitigating development risks.
Basic / Conventional Formulations
Early-stage solutions, suspensions, IR tablets, simple injectables for tox and FIH studies, built for speed and clinical relevance.
Non-Conventional Formulations
Includes lipidic systems, suspensions for parenteral use, semi-solid injectables, and structurally complex matrices.
Specialty Formulations
Ocular, inhalation, intranasal, rectal, transungual, and pediatric formulations requiring precision dosing and high tolerability.
Advanced Delivery Systems
Liposomal, polymeric nanoparticle, nanoemulsion, microsphere-based, and implantable delivery architectures.
Solubility-Enhancement Formulations
ASD, nano-systems, microemulsions, salt screens, cocrystals, and pH-shift strategies for insoluble or highly lipophilic APIs.
Bioavailability-Enhanced Formulations
SMEDDS, SEDDS, supersaturation systems, surfactant-enabled systems, and permeability enhancers.
Prodrug-Based Formulations
Design and stabilization of labile prodrug systems, enzymatic release mapping, and PK/PD alignment.
Device or Delivery-Component Modification
Rapid feasibility tools including screening formulations, hot-melt extrudates, spray-dried dispersions, and animal PK enabling formats.